MoonLake Immunotherapeutics (MLTX) Notes Payables (2020 - 2022)

MoonLake Immunotherapeutics' Notes Payables history runs 3 years deep, the most recent figure standing at $150000.0 for Q1 2022.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $150000.0 in Q1 2022; TTM through Mar 2022 was $150000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $15.0 million, up 25734.01% from the prior year.
• Notes Payables fell to $150000.0 in Q1 2022 per MLTX's latest filing, from $15.0 million in the prior quarter.
• Across five years, Notes Payables topped out at $15.0 million in Q4 2021 and bottomed at $58063.0 in Q4 2020.
• The 3-year median for Notes Payables is $150000.0 (2022), against an average of $5.1 million.
• Biggest YoY gain for Notes Payables was 25734.01% in 2021; the steepest drop was 25734.01% in 2021.
• Year by year, Notes Payables stood at $58063.0 in 2020, then soared by 25734.01% to $15.0 million in 2021, then plunged by 99.0% to $150000.0 in 2022.
• Per Business Quant, the three latest MLTX Notes Payables figures stand at $150000.0 (Q1 2022), $15.0 million (Q4 2021), and $58063.0 (Q4 2020).